Moscow, 19 October, 2009 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announces its unaudited IFRS sales results for the nine-month period ended 30 September 2009. The total revenue of the Company for the nine months of 2009 amounted to RUR14,539 , an increase of 40% over 9m2008.
Sales
Pharmstandard’s sales for the nine months of 2009 increased by 40% to RUR14,539 million, which represents the increase of RUR4,179 million in comparison with RUR10,360 million reported in the same period of 2008. Pharmaceutical products and medical equipment sales contributed 97% and 3% of total sales respectively.
The Company’s sales of pharmaceutical products achieved RUR14,103 million for the nine months of 2009 and increased by 47% compared to prior-year period. Pharmaceutical products organic sales growth excluding Velcade® and Mildronate® sales was 27%.
The sales of OTC products were RUR9,319 million for the nine months of 2009 and grew by 24% in comparison with nine-month period of 2008. Arbidol®, IRS19®, Afobazol®, Imudon®, Pentalgin®, Complivit®, Codelac® and Amixin® generated key sales growth in OTC segment.
The Company’s revenue from prescription (Rx) products amounted to RUR4,727 million and increased by 138% compared with the same period of 2008. The prescription products sales were driven not only by an increase in leading brands sales, such as Phosphogliv®, Combilipen® (launched in 2008), Rastan®, Pikamilon®, Biosulin®, and Azitrox® but also by successful implementation of Velcade® (sales – RUR2,278 for 9m2009) and Mildronate® (sales – RUR805 for 9m2009) projects. Rx segment organic growth excluding Velcade® and Mildronate® sales was 50%.
The Company’s revenue from its medical equipment business totaled RUR435 mln for the nine months of 2009, which represents a 45% decline in comparison with the same period of 2008.
Sales structure – 9m 2009, RUR mln.
|
9M 2009 |
2009 (mln RUR) |
2008 (mln RUR) |
Difference (mln RUR) |
Difference (%) |
|
Pharmaceutical products |
14 103 |
9 563 |
4 541 |
47% |
|
OTC products |
9 319 |
7 545 |
1 774 |
24% |
|
Branded products |
7 870 |
6 494 |
1 377 |
21% |
|
Non-branded products |
1 449 |
1 051 |
398 |
38% |
|
Prescription products |
4 727 |
1 984 |
2 743 |
138% |
|
Branded products |
4 412 |
1 767 |
2 645 |
150% |
|
Mildronate |
805 |
889 |
-84 |
-9% |
|
Velcade |
2 278 |
0 |
2 278 |
- |
|
Non-branded products |
314 |
217 |
98 |
45% |
|
Other sales |
58 |
34 |
24 |
71% |
|
Medical equipment and disposables |
435 |
797 |
-362 |
-45% |
|
Total sales |
14 539 |
10 360 |
4 179 |
40% |
Sales structure – 3q 2009, RUR mln.
|
3Q 2009 |
2009 (mln RUR) |
2008 (mln RUR) |
Change (mln RUR) |
% 09 to 08 |
|
Pharmaceutical products |
4 315 |
3 891 |
425 |
11% |
|
OTC products |
3 588 |
3 221 |
366 |
11% |
|
Branded products |
3 035 |
2 764 |
271 |
10% |
|
Non-branded products |
553 |
457 |
96 |
21% |
|
Prescription products |
712 |
657 |
55 |
8% |
|
Branded products |
572 |
547 |
25 |
5% |
|
Mildronate |
131 |
261 |
-130 |
-50% |
|
Velcade |
0 |
0 |
0 |
- |
|
Non-branded products |
140 |
110 |
30 |
27% |
|
Other sales |
15 |
13 |
2 |
15% |
|
Medical equipment and disposables |
162 |
270 |
-108 |
-40% |
|
Total sales |
4 477 |
4 161 |
316 |
8% |
Conference Call
Pharmstandard is pleased to invite the investment community to a sales results conference call with the management of the company followed by a Q&A session.
Monday, October 19, 2009
09:00 New York
14:00 London
17:00 Moscow
To join the conference please register on-line in advance using the link below:
https://eventreg1.conferencing.com/webportal3/reg.html?Acc=916302&Conf=168893
or dial:
International Call-in Number: +44 (0)20 7162 0025
US Toll Number : +1 334 323 6201
We recommend that participants start dialling in 5-10 minutes prior to ensure a timely start to the conference call.
Conference call presentation will be available on Monday, 19 October 2009 on Company’s web-site:
https://www.pharmstd.ru/investors_en/investor/p2/
Pharmstandard will be represented by:
Igor Krylov, CEO
Elena Arkhangelskaya, CFO
The conference call replay will be available through October 22, 2009.
International Replay Number: +44 (0)20 7031 4064
US Toll Replay Number: +1 954 334 0342
Replay Access Code: 848065
| 
